An interventional study of multiple health education interventions and conventional health education in Ischemic Stroke, sponsored by yongjun wang. Completed at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-12-11.
Sponsored by yongjun wang · Not applicable, Interventional, and Prevention
The purpose of this study is to assess the affect of multiple health education interventions for statins medication Persistence and clinical prognosis of ischemic stroke patients at 3, 6 and 12 months.
The study is a prospective, multicenter, hospital-based study on secondary prevention for patients with ischemic cerebrovascular diseases between May 2014 and June 2015. Physicians from 24 hospitals in Beijing underwent a standard secondary prevention training of ischemic cerebrovascular diseases by professional training, instruction manuals, stratification management software. In order to improve the persistence of taking preventive secondary medicine, IS patients from these 24 hospitals received healthy education through manuals and Digital Video Disc about health education during hospitalization and acquired secondary preventive knowledge of ischemic cerebrovascular diseases through regular health education messages during 6 months after discharge. Patients with IS from other 6 hospitals were used as a control, and no such intervention was given to them.
Telephone follow-up was performed at 3 months, 6 months, and 1 year after the onset of cerebral infarction, during which the use of antiplatelet and statins drugs and recurrence of IS were recorded. Patients who took antiplatelet drugs or statins at three follow-ups were regarded as persistent antiplatelet drugs or statins taking within one year after the onset of the disease. The main prognostic indicator was the recurrence of IS and persistence of statins medication within 1 year, and the main purpose was to explore the impact of persistent statins use on IS recurrence.
7,286 studies on the registry are indexed under Stroke; 2,013 are open to participants now.
This study's enrollment of 3,111 is above the median of 50 across 5,366 interventional studies indexed under Stroke.
Browse Stroke studies →yongjun wang is the lead sponsor of 5 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
The first group will receive health education manuals and Digital Video Disc (DVD) during hospitalization and regular health education messages during 6 months after discharge.
Behavioral: multiple health education interventions
The second group will receive conventional health education during hospitalization except health education manuals, regular health education messages and Digital Video Disc (DVD)
Behavioral: conventional health education
Proportion of patients who continued taking statins drugs at three months after stroke onset.
Statins Medication persistence at 3 months. Patients who took statins at three months follow-up were regarded as persistent during three months.
Time frame: 3 months after stroke onset
Proportion of patients who continued taking statins drugs at six months after stroke onset.
Statins Medication persistence at 6 months.Patients who took statins at six months follow-up were regarded as persistent at six months.
Time frame: 6 months after stroke onset
Proportion of patients who continued taking statins drugs at 12 months after stroke onset.
Statins Medication persistence at 12 months.Patients who took statins at twelve months follow-up were regarded as persistent at twelve months.
Time frame: 12 months after stroke onset
Proportion of patients who continued taking statins drugs in 1 year after stroke onset.
Statins Medication persistence in 1 year: Patients who took statins at 3, 6 and 12 months follow-up were regarded as persistent during one year after stroke onset.
Time frame: 1 year after stroke onset
Recurrence of ischemic stroke in three months after stroke onset
Recurrence of ischemic stroke was defined as a new focal neurological deficit of vascular origin lasting \>24 hours and without hemorrhage on computed tomography or MRI of the brain.
Time frame: 3 months after stroke onset
Recurrence of ischemic stroke in six months after stroke onset
Recurrence of ischemic stroke was defined as a new focal neurological deficit of vascular origin lasting \>24 hours and without hemorrhage on computed tomography or MRI of the brain.
Time frame: 6 months after stroke onset
Recurrence of ischemic stroke in 12 months after stroke onset
Recurrence of ischemic stroke was defined as a new focal neurological deficit of vascular origin lasting \>24 hours and without hemorrhage on computed tomography or MRI of the brain.
Time frame: 12 months after stroke onset
Percentage of patients with 3-month poor clinical prognosis (including Death or Nonfatal myocardial infarction or Nonfatal hemorrhagic stroke or Severe disabilities) as a cluster and evaluated individually
Death included Vascular death and non-vascular death; Severe disabilities was defined as modified Rankin Scale ≥4
Time frame: 3 months after stroke onset
Percentage of patients with 6-month poor clinical prognosis (including Death or Nonfatal myocardial infarction or Nonfatal hemorrhagic stroke or Severe disabilities) as a cluster and evaluated individually
Death included Vascular death and non-vascular death; Severe disabilities was defined as modified Rankin Scale ≥4
Time frame: 6 months after stroke onset
Percentage of patients with 12-month poor clinical prognosis (including Death or Nonfatal myocardial infarction or Nonfatal hemorrhagic stroke or Severe disabilities) as a cluster and evaluated individually
Death included Vascular death and non-vascular death; Severe disabilities was defined as modified Rankin Scale ≥4
Time frame: 12 months after stroke onset
This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
yongjun wang